Silence Therapeutics is the leading RNAi therapeutics company in Europe. The Company has developed novel, proprietary short interfering RNA (“siRNA”) molecules. These molecules provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells in the body, whilst increasing their bioavailability and circulation times.